Bofanglutide Update Marks Major Progress in Gan & Lee’s GRADUAL-3 Study

 Bofanglutide update highlights Gan & Lee’s launch of the GRADUAL-3 phase 3 trial testing once-monthly injections to support sustained weight loss and adherence

Gan & Lee Pharmaceuticals has announced a major step forward in obesity drug development with the initiation of GRADUAL-3, its third large-scale phase 3 clinical study evaluating the GLP-1 receptor agonist bofanglutide (GZR18). The latest bofanglutide update highlights the company’s focus on exploring a once-monthly injection designed to support sustained weight loss and improve long-term adherence.

Study Design Focuses on Weight Change After 24 Weeks

The 24-week study (CTR20254659), led by Professor Linong Ji of Peking University People’s Hospital, will examine both the absolute and percentage change in body weight after continuous treatment. According to a recent bofanglutide update, the trial will play a critical role in demonstrating whether reduced injection frequency can maintain weight-loss results in adults with obesity or overweight.

Earlier GRADUAL Trials Show Strong Comparative Performance

GRADUAL-3 builds on insights from GRADUAL-1 and GRADUAL-2, two major phase 3 studies already underway. GRADUAL-2 is especially notable for being the world’s first head-to-head comparison of bofanglutide and semaglutide 2.4 mg (Wegovy) in Chinese adults with obesity or overweight. These studies collectively aim to confirm the treatment’s safety, weight-loss efficacy, and broader metabolic benefits. Each bofanglutide update has reinforced confidence in the drug’s potential to compete in the expanding GLP-1 landscape.

Once-Monthly Dose Expected to Improve Long-Term Adherence

Researchers expect the once-monthly regimen in GRADUAL-3 to address persistent challenges in GLP-1 therapy, including declining adherence, weight regain, and the reduced durability of weight-loss results over time. As indicated in another bofanglutide update, simplifying dosing could significantly strengthen long-term patient outcomes.

Gan & Lee Expands Its Portfolio of Metabolic Therapies

The GRADUAL clinical development programme now includes three ongoing phase 3 trials involving more than 1,000 planned participants across China. Meanwhile, bofanglutide continues to advance globally as a promising therapy for obesity and type 2 diabetes, with a safety profile comparable to marketed GLP-1 RAs. With every new bofanglutide update, Gan & Lee reinforces its commitment to metabolic innovation, building on a legacy that includes China’s first domestic insulin analog and a robust portfolio of six core insulin products.